Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Last Updated: Monday, June 14, 2021
Data from the LOTIS-2 trial—upon which the recent FDA approval for loncastuximab tesirine was based—showed that patients with relapsed/refractory diffuse large B-cell lymphoma benefit from the antibody-drug conjugate, with a 48.3% overall response rate.
Advertisement
News & Literature Highlights
